Company: SHPH
Filing Date: 2025-04-21
Form Type: DEFR14A
Source: 0001641172-25-005474
Chunk: 20

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-04-21
Form: DEFR14A
Chunk 20
---
 |       | 236,000 |
|                                     |     |      | 2023 |     |        | 242,012 |     |       |  72,000 |     |        |         |     |        | - |     |                                 | - |     |                                | - |     |                    | - |     |       | 314,012 |
| Tyvin Rich, Chief Medical Officer   |     |      | 2024 |     |        | 218,000 |     |       |       - |     |        |       - |     |        | - |     |                                 | - |     |                                | - |     |                    | - |     |       | 218,000 |
|                                     |     |      | 2023 |     |        | 220,226 |     |       |  43,000 |     |        |       - |     |        | - |     |                                 | - |     |                                | - |     |                    | - |     |       | 263,226 |

* Dr. Dritschilo served as Chief Executive Officer since the Company’s formation in December 2012. In March 2025, Dr. Dritschilo assumed the role of Chief Scientific Officer, with his role focused on overseeing clinical trials and scientific development at the Company, while remaining in the position of Chairman of the Board of Directors.

**Michael Vander Hoek served as CFO through June 12, 2024, at which time Timothy Lorber assumed the position of CFO on a part-time basis commencing June 13, 2024 and became full-time CFO on September 9, 2024.

| 15 |

Each of our executive officers has entered into
an employment agreement with us. The employees each will receive compensation on an annual basis in cash, payable in monthly installments
commencing at the completion of our IPO, as well as restricted stock units (“RSUs”) subject to achieving certain key performance
indicators. Certain of our executive officers are entitled to various target bonuses, upon achievement of certain milestones. The terms
of the employment agreements are as follows:

Employment Agreement with Anatoly Dritschilo, MD

On June 28, 2019, we entered into an employment agreement with our then Chief Executive Officer and Chairman of the Board of Directors, Anatoly Dritschilo, M.D, which was amended and restated on March 31, 2025 to account